Your browser is no longer supported. Please, upgrade your browser.
Settings
BCAB [NASD]
BioAtla, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own6.60% Shs Outstand33.68M Perf Week-8.86%
Market Cap1.17B Forward P/E- EPS next Y-3.54 Insider Trans-32.35% Shs Float27.03M Perf Month-15.09%
Income-77.10M PEG- EPS next Q-0.64 Inst Own66.40% Short Float10.71% Perf Quarter-12.64%
Sales0.40M P/S2920.34 EPS this Y-24.80% Inst Trans11.71% Short Ratio11.48 Perf Half Y-49.19%
Book/sh5.29 P/B6.53 EPS next Y-32.10% ROA- Target Price- Perf Year-
Cash/sh6.14 P/C5.63 EPS next 5Y- ROE- 52W Range27.15 - 76.63 Perf YTD1.59%
Dividend- P/FCF- EPS past 5Y- ROI-15.70% 52W High-54.91% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low27.26% ATR1.99
Employees36 Current Ratio5.90 Sales Q/Q50.00% Oper. Margin- RSI (14)29.73 Volatility5.35% 5.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-365.20% Profit Margin- Rel Volume5.14 Prev Close36.67
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume252.35K Price34.55
Recom1.60 SMA20-12.66% SMA50-13.99% SMA200-23.37% Volume1,296,194 Change-5.78%
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jan-11-21Initiated Credit Suisse Outperform $49
Jan-11-21Initiated BTIG Research Buy $47
Sep-12-21 08:49AM  
Aug-13-21 05:54PM  
Jun-14-21 02:03AM  
May-12-21 06:26PM  
Mar-16-21 01:59AM  
Dec-18-20 04:00PM  
Dec-16-20 05:34PM  
04:52PM  
Dec-15-20 07:59PM  
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorSep 15Sale36.8245016,56918,909Sep 17 02:05 PM
Sievers EricChief Medical OfficerAug 26Sale39.596,883272,49693,766Aug 30 09:42 PM
Smith Scott AndrewPresidentAug 26Sale40.1633,2441,334,927354,719Aug 30 09:43 PM
SHORT JAY M PHDChief Executive OfficerAug 24Option Exercise18.007,747139,446798,080Aug 26 05:41 PM
SHORT JAY M PHDChief Executive OfficerAug 24Sale41.604,533188,573793,547Aug 26 05:41 PM
Levy GuyDirectorAug 24Sale39.65546,70921,677,012217,358Aug 26 08:05 PM
STEINMAN LAWRENCEDirectorAug 16Sale40.6045018,27019,359Aug 18 05:48 PM
STEINMAN LAWRENCEDirectorJul 15Sale38.2945017,23019,809Jul 19 09:25 PM
SHORT JAY M PHDChief Executive OfficerJun 21Sale39.1355,0002,152,373790,333Jun 22 07:39 PM
SHORT JAY M PHDChief Executive OfficerJun 17Sale39.2219,269755,753845,333Jun 22 07:39 PM
Levy GuyDirectorJun 17Sale39.16400,00015,664,000270,553Jun 21 04:30 PM
Levy GuyDirectorDec 18Buy18.001,388,89025,000,0201,055,557Dec 22 04:30 PM
Cormorant Asset Management, LPFormer 10% OwnerDec 18Buy18.00800,00014,400,0002,292,060Dec 22 04:09 PM